San Diego, CA -- (SBWIRE) -- 08/12/2015 -- An investigation for investors in NASDAQ:AMAG shares over potential securities laws violations by AMAG Pharmaceuticals and certain of its directors and officers in connection certain financial statements was announced.

Investors who purchased shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) concerning whether a series of statements by AMAG Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On June 3, 2014, AMAG Pharmaceuticals, Inc disclosed that on June 2, 2014, AMAG Pharmaceuticals, Inc proposed to the U.S. Food and Drug Administration ("FDA") changes to the current U.S. label of Feraheme Injection based on a review of global post-marketing data.

On January 9, 2015, AMAG Pharmaceuticals, Inc disclosed that on January 7, 2015, after considering AMAG Pharmaceuticals' June 2014 submission and other information, the FDA notified AMAG Pharmaceuticals that it believes new safety information should be included in the labeling of Feraheme, including, among other things, a boxed warning to highlight the risks of serious hypersensitivity/anaphylaxis reactions and revisions that Feraheme should only be administered through an intravenous ("IV") infusion, (i.e., not by IV injection), and should be contraindicated for patients with any known history of drug allergy. The FDA's recommended label changes go beyond what AMAG Pharmaceuticals proposed in June 2014.

On July 23, AMAG Pharmaceuticals, Inc reported unaudited consolidated financial results for the second quarter and year-to-date periods ended June 30, 2015.

On July 27, 2015, AMAG Pharmaceuticals, Inc stated in its 10Q report that on July 20, 2015, the Federal Trade Commission (the "FTC") notified AMAG Pharmaceuticals, Inc that it is conducting an investigation with respect to Makena or any hydroxyprogesterone caproate product. AMAG Pharmaceuticals, Inc said that the FTC noted that the existence of the investigation does not indicate that the FTC has concluded that Lumara Health or its predecessor has violated the law. Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) declined to as low as $62.23 per share on July 27, 2015.

On August10, 2015, NASDAQ:AMAG shares closed at $65.68 per share.

Those who purchased shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com